Please login to the form below

Not currently logged in

Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month

Monoclonal antibody has neutralised SARS-CoV-2 virus in vitro

US-based Vir Biotech has plans to begin a mid-to-late stage study of its COVID-19 drug this month, following promising results in early studies.

The candidate, VIR-7832, is a monoclonal antibody that has demonstrated the ability to neutralise the SARS-CoV-2 virus, which causes COVID-19, in vitro. The drug has also demonstrated a high barrier to resistance and an ability to recruit immune cells to kill already infected cells.

Based on these characteristics, Vir hopes that the drug can achieved clinical efficacy in large-scale human trials. Following the initiation of trials this month, the company hopes to have initial clinical data available before the end of the year.

The clinical programme for VIR-7831 includes trials for early and hospitalised treatment of COVID-19 patients, as well as a prevention medication.

In May, Vir signed a deal with Biogen to develop and manufacture antibodies for the potential treatment of COVID-19. This included VIR-7831 and another antibody candidate, VIR-7832.

Under the terms of this agreement, Biogen will perform process development activities and specified manufacturing/process transfer services to enable commercial supply of Vir’s antibody treatments.

“Biogen’s world-class cell line and process development expertise is a tremendous asset as we work with great urgency to develop our antibody candidates, including employing technology that is designed to maximise the yield of each manufacturing batch produced,” said Michael Kamarck, chief technology officer of Vir.

Vir has also contracted with Biogen to conduct cGMP clinical manufacturing in the US, and provide technical support to aid rapid process transfer to large-scale biomanufacturing facilities in the US and other region across the globe.

This agreement will ensure that a reliable supply of the potential commercial product is ensured and can meet demand in key markets.

Vir also expects to begin a phase 2 trial of VIR-7832 this year – the drug shares the same promising characteristics as VIR-7831 but could also function as a therapeutic as well as a preventative T-cell vaccine.

The company also expects to complete preclinical studies of an inhaled SARS-CoV-2 targeting siRNA treatment, VIR-2703, by the end of the year.

Article by
Lucy Parsons

12th August 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...